Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149175164> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2149175164 endingPage "A286" @default.
- W2149175164 startingPage "A286" @default.
- W2149175164 abstract "Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia affecting approximately 40,000 to 80,000 inhabitants in Costa Rica. AF increases stroke, thrombo-embolism, deaths, heart failure and hospitalizations rates, affecting the quality of life and raising overall costs. Literature suggests anticoagulation is the best strategy to prevent strokes and reduce death rates in AF. The aim of this study was to assess the cost-effectiveness (CE) of warfarin against Apixaban, Rivaroxaban, and Dabigatran as therapy for AF, from the public health care perspective. A simulated cohort of patients with AF entered a decision-tree model to compare costs and effectiveness of Warfarin (5 mg/day) (comparator), Apixaban (5 mg/12 hours), Dabigatran (110 mg/12 hours and 150 mg/12 hours), and Rivaroxaban (20 mg/day). Effectiveness measures were: stroke, bleeding and myocardial infarction (MI) rates and deaths. The model used a lifetime horizon and only direct medical costs were considered (inpatient costs, medication expenses, adverse events costs, tests). Effectiveness and epidemiologic data were retrieved from published literature. Local costs (US$ 2012) were gathered from the Social Security of Costa Rica official databases. Apixaban resulted as the less expensive option for AF in adult patients and it was the only treatment that consistently prevented all three considered diseases: Three MIs, 18 strokes, 54 bleedings avoided when compared to Warfarin. Mortality rate was found to be similar with all strategies implemented. Overall costs were US$43,211,440.23 for warfarin, US$38,240,522.33 for Apixaban (lowest), US$38,458,665.03 for Dabigatran 110 mg, US$41,055,937.68 for Dabigatran 150 mg, and US$42,551,663.86 for Rivaroxaban. In the CE incremental analysis, Apixaban appeared as a cost-saving option. Apixaban obtained the highest probability of being cost-effective with a 3 GPB per capita in Costa Rica. PSA results support the robustness of these findings. Apixaban resulted as the cost-saving therapy for AF adult patients in Costa Rica." @default.
- W2149175164 created "2016-06-24" @default.
- W2149175164 creator A5012027205 @default.
- W2149175164 creator A5033002544 @default.
- W2149175164 creator A5038613497 @default.
- W2149175164 creator A5047807912 @default.
- W2149175164 creator A5066178045 @default.
- W2149175164 creator A5082291566 @default.
- W2149175164 creator A5088916649 @default.
- W2149175164 creator A5091320016 @default.
- W2149175164 date "2013-05-01" @default.
- W2149175164 modified "2023-09-30" @default.
- W2149175164 title "Economic evaluation of apixaban for atrial fibrillation in costa Rica" @default.
- W2149175164 doi "https://doi.org/10.1016/j.jval.2013.03.1485" @default.
- W2149175164 hasPublicationYear "2013" @default.
- W2149175164 type Work @default.
- W2149175164 sameAs 2149175164 @default.
- W2149175164 citedByCount "2" @default.
- W2149175164 countsByYear W21491751642013 @default.
- W2149175164 countsByYear W21491751642023 @default.
- W2149175164 crossrefType "journal-article" @default.
- W2149175164 hasAuthorship W2149175164A5012027205 @default.
- W2149175164 hasAuthorship W2149175164A5033002544 @default.
- W2149175164 hasAuthorship W2149175164A5038613497 @default.
- W2149175164 hasAuthorship W2149175164A5047807912 @default.
- W2149175164 hasAuthorship W2149175164A5066178045 @default.
- W2149175164 hasAuthorship W2149175164A5082291566 @default.
- W2149175164 hasAuthorship W2149175164A5088916649 @default.
- W2149175164 hasAuthorship W2149175164A5091320016 @default.
- W2149175164 hasBestOaLocation W21491751641 @default.
- W2149175164 hasConcept C112930515 @default.
- W2149175164 hasConcept C126322002 @default.
- W2149175164 hasConcept C127413603 @default.
- W2149175164 hasConcept C164705383 @default.
- W2149175164 hasConcept C177713679 @default.
- W2149175164 hasConcept C194828623 @default.
- W2149175164 hasConcept C2776301958 @default.
- W2149175164 hasConcept C2778661090 @default.
- W2149175164 hasConcept C2778810321 @default.
- W2149175164 hasConcept C2779161974 @default.
- W2149175164 hasConcept C2780638905 @default.
- W2149175164 hasConcept C2780645631 @default.
- W2149175164 hasConcept C3019080777 @default.
- W2149175164 hasConcept C71924100 @default.
- W2149175164 hasConcept C72563966 @default.
- W2149175164 hasConcept C78519656 @default.
- W2149175164 hasConceptScore W2149175164C112930515 @default.
- W2149175164 hasConceptScore W2149175164C126322002 @default.
- W2149175164 hasConceptScore W2149175164C127413603 @default.
- W2149175164 hasConceptScore W2149175164C164705383 @default.
- W2149175164 hasConceptScore W2149175164C177713679 @default.
- W2149175164 hasConceptScore W2149175164C194828623 @default.
- W2149175164 hasConceptScore W2149175164C2776301958 @default.
- W2149175164 hasConceptScore W2149175164C2778661090 @default.
- W2149175164 hasConceptScore W2149175164C2778810321 @default.
- W2149175164 hasConceptScore W2149175164C2779161974 @default.
- W2149175164 hasConceptScore W2149175164C2780638905 @default.
- W2149175164 hasConceptScore W2149175164C2780645631 @default.
- W2149175164 hasConceptScore W2149175164C3019080777 @default.
- W2149175164 hasConceptScore W2149175164C71924100 @default.
- W2149175164 hasConceptScore W2149175164C72563966 @default.
- W2149175164 hasConceptScore W2149175164C78519656 @default.
- W2149175164 hasIssue "3" @default.
- W2149175164 hasLocation W21491751641 @default.
- W2149175164 hasOpenAccess W2149175164 @default.
- W2149175164 hasPrimaryLocation W21491751641 @default.
- W2149175164 hasRelatedWork W1972269502 @default.
- W2149175164 hasRelatedWork W1993190469 @default.
- W2149175164 hasRelatedWork W2006773714 @default.
- W2149175164 hasRelatedWork W2013904527 @default.
- W2149175164 hasRelatedWork W2021252689 @default.
- W2149175164 hasRelatedWork W2039688335 @default.
- W2149175164 hasRelatedWork W2896204226 @default.
- W2149175164 hasRelatedWork W2979702411 @default.
- W2149175164 hasRelatedWork W2990629389 @default.
- W2149175164 hasRelatedWork W3016213733 @default.
- W2149175164 hasVolume "16" @default.
- W2149175164 isParatext "false" @default.
- W2149175164 isRetracted "false" @default.
- W2149175164 magId "2149175164" @default.
- W2149175164 workType "article" @default.